Issue of Equity and Total Voting Rights
SkinBioTherapeutics plc has announced the issuance of 259,472 new ordinary shares, valued at 1 pence each, pursuant to a share option agreement with a former employee. These new shares will be admitted to trading on the AIM Market of the London Stock Exchange on 13 February 2026, at which point the company's total voting rights will increase to 259,168,671 ordinary shares. This figure will serve as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
11 February 2026 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it has issued, conditional on admission, 259,472 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the share options agreement entered into by the Company and a previous employee upon IPO.
The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 13 February 2026.
Total Voting Rights
Following Admission, the Company will have 259,168,671 Ordinary Shares in issue. This figure of 259,168,671 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.